MARKET

SVA

SVA

Sinovac Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.47
0.00
0.00%
Suspension 16:00 10/19 EDT
OPEN
--
PREV CLOSE
6.47
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
6.25
MARKET CAP
639.90M
P/E (TTM)
88.15
1D
5D
1M
3M
1Y
5Y
N.Korea gets offers of aid to fight COVID as it lacks vaccines
reuters.com · 05/13 07:19
COVID SCIENCE-Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants
reuters.com · 05/06 17:13
BRIEF-Sinovac Updates The Status Under Holding Foreign Companies Accountable Act
reuters.com · 05/06 11:04
Sinovac Biotech GAAP EPS of $74.27, revenue of $19.4B
Sinovac Biotech press release (NASDAQ:SVA): FY GAAP EPS of $74.27. Revenue of $19.4B (+3699.5% Y/Y). Non-GAAP adjusted EBITDA was $17.6B in 2021, compared to $229.9M in the prior year. As
Seekingalpha · 05/02 07:48
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
BEIJING, China, April 29, 2022--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for t...
Business Wire · 04/29 22:30
Sinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong Kong
Sinovac Biotech's (NASDAQ:SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong. Sinovac, a unit of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY), said preclinical studies showed that the SINOVAC Omicron variant inactivated vaccine was ...
Seekingalpha · 04/18 08:29
Global group call for $15 billion this year for long term COVID response
A group of global institutions led by the International Monetary Fund (IMF) has proposed $15 billion in grants this year and $10 billion annually thereafter as part of a global
Seekingalpha · 04/05 16:24
COVID SCIENCE-Vaccination after COVID improves immunity; ivermectin fails in major trial
reuters.com · 04/01 17:26
More
No Data
Learn about the latest financial forecast of SVA. Analyze the recent business situations of Sinovac Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
WeiDong Yin
Chief Financial Officer/Vice President
Nan Wang
Chief Operating Officer/Vice President
Qiang Gao
Vice President
Jing Li
Independent Director
Simon Anderson
Independent Director
Shan Fu
Independent Director
Kenneth Lee
Independent Director
Yuk Lam Lo
Independent Director
Meng Mei
No Data
No Data
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Webull offers kinds of Sinovac Biotech Ltd. stock information, including NASDAQ:SVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVA stock methods without spending real money on the virtual paper trading platform.